“While orphan drugs’ share of the $880-billion global pharmaceuticals market remains small—at $50 billion as of the end of 2011, or just 6% of the total—their growth curve has been steep. Thomson Reuters reports that between 2001 and 2010, orphan drugs posted a compound annual growth rate of 25.8%, outstripping the 20.1% CAGR returned by a matched non-orphan control group. With these kinds of eye-popping profits being raked in by orphan drug makers, the investment world has taken notice.”
http://www.caseyresearch.com/cdd/orphans-adding-company-value-in-the-biotech-space
Related posts:
California wants to ban campfires at the beach
Bitcoin Wallet Extension Disappears From Chrome Due To Anti-Malware
Japanese Bitcoin Exchange Shuts Down After $723M Stolen
Original owner of Toronto ex-mayor’s alleged ‘crack’ video may have been killed
Meet “badBIOS,” the mysterious malware that jumps airgaps
Stolen Public School Textbooks Went Unnoticed for Five Years.
Texas woman stripped and jailed over unpaid traffic ticket
Directed History of the Swiss Tax Settlement
College tuition increases more than triple the rate of inflation
National Lawyers Guild Report Supports Further Marijuana Legalization Initiatives
Frankenfish and Other Stupid Industrial Food Tricks
Internationalizing the Internet
And the Media Gets It Wrong (Again)
US military wants a portable, bullet-resistant wall that fits in a can
Swedish Man Faces 2 Years in Prison For Saying Somalis Have Low IQ